Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: PTGES3

Summary for PTGES3

Gene information	Gene symbol	PTGES3
	Ensembl ID	ENSG00000110958
	Entrez ID	10728
	Gene name	prostaglandin E synthase 3
	Synonyms	cPGES\|p23\|TEBP
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: PTGES3

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.325088	1.13e-33
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.273026	5.35e-15
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.267668	8.70e-37
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.315375	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.261636	1.40e-44
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.295185	4.30e-04
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.622236	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.253238	1.29e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.275737	3.80e-06
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.518578	3.41e-23
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.669392	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.532514	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	-0.37162	4.54e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.341473	1.11e-07
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.800718	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.636284	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.701477	4.10e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.41922	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.587073	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.581636	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.968027	0.00e+00
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	0.275452	1.29e-14
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.77874	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.410193	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.38119	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.632525	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.277932	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.379489	0.00e+00

Top

Expression of PTGES3 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to PTGES3

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating PTGES3

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
PTGES3	hsa-miR-4668-3p	97.4578	NM_001282601
PTGES3	hsa-miR-1206	93.1822	NM_001282601
PTGES3	hsa-miR-5187-3p	90.9023	NM_001282601
PTGES3	hsa-miR-7843-3p	90.7243	NM_001282601
PTGES3	hsa-miR-376c-3p	89.4304	NM_001282601
PTGES3	hsa-miR-4428	88.7475	NM_001282601
PTGES3	hsa-miR-378i	88.6479	NM_001282601
PTGES3	hsa-miR-378a-3p	88.6479	NM_001282601
PTGES3	hsa-miR-378d	88.6479	NM_001282601
PTGES3	hsa-miR-422a	88.6479	NM_001282601
PTGES3	hsa-miR-378h	88.6479	NM_001282601
PTGES3	hsa-miR-378c	88.6479	NM_001282601
PTGES3	hsa-miR-378e	88.6479	NM_001282601
PTGES3	hsa-miR-378b	88.6479	NM_001282601
PTGES3	hsa-miR-378f	88.6479	NM_001282601
PTGES3	hsa-miR-6504-3p	87.9112	NM_001282601
PTGES3	hsa-miR-3135a	86.9953	NM_001282601
PTGES3	hsa-miR-6833-3p	85.624	NM_001282601
PTGES3	hsa-miR-4768-5p	85.624	NM_001282601
PTGES3	hsa-miR-4803	85.4662	NM_001282601
PTGES3	hsa-miR-513c-5p	85.3972	NM_001282601
PTGES3	hsa-miR-10399-5p	84.8573	NM_001282601
PTGES3	hsa-miR-4266	84.2499	NM_001282601
PTGES3	hsa-miR-3189-5p	83.7016	NM_001282601
PTGES3	hsa-miR-4286	83.574	NM_001282601
PTGES3	hsa-miR-510-5p	82.149	NM_001282601
PTGES3	hsa-miR-4506	81.7917	NM_001282601
PTGES3	hsa-miR-454-3p	80.3231	NM_001282601
PTGES3	hsa-miR-152-3p	80.2794	NM_001282601
PTGES3	hsa-miR-148a-3p	80.2794	NM_001282601
PTGES3	hsa-miR-148b-3p	80.2794	NM_001282601
PTGES3	hsa-miR-4776-3p	80.0593	NM_001282601

Page: 1

Top

Motifs and transcription factors (TFs) regulating PTGES3

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
PTGES3	transfac_public__M00278	GATA1; LDB1; LMO2; TAL1; TCF3 (inferredBy_Orthology).
PTGES3	transfac_pro__M06214	ZNF33B (directAnnotation).
PTGES3	kznf__ZFP57_Imbeault2017_RP_ChIP-seq	ZFP57 (directAnnotation).
PTGES3	metacluster_195.2	EGR2; KLF10; KLF10; KLF11; KLF11; KLF11; KLF13; KLF13; KLF13; KLF13; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF15; KLF15; KLF16; KLF3; KLF8; KLF9; KLF9; KLF9; SP1; SP1; SP1; SP3; SP3; SP4; SP8; SP8; SP8; SP9; SP9 (directAnnotation). EGR1; KLF1; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF2; KLF3; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF9; SP1; SP3; SP4; SP4; SP5; SP5; SP5; SP6; SP7; SP8; SP9 (inferredBy_Orthology).
PTGES3	metacluster_67.2	ZNF501 (directAnnotation). ACAA1; E2F2; E2F2; E2F3; E2F3; FOXN4 (inferredBy_Orthology).
PTGES3	cisbp__M07938	E2F1 (directAnnotation).
PTGES3	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
PTGES3	dbtfbs__E2F8_representative_N1	E2F8 (directAnnotation).
PTGES3	transfac_pro__M04950	EGR1 (directAnnotation).
PTGES3	metacluster_15.3	E2F1; E2F6; E2F8; E2F8; TFDP1 (directAnnotation). E2F3 (inferredBy_Orthology).
PTGES3	metacluster_197.2	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).
PTGES3	transfac_pro__M00652	NRF1 (directAnnotation).
PTGES3	transfac_pro__M04866	HDAC2 (directAnnotation).
PTGES3	jaspar__MA1122.1	TFDP1 (directAnnotation).
PTGES3	metacluster_34.1	ZNF143; ZNF143; ZNF143; ZNF76; ZNF76; ZNF76 (directAnnotation).
PTGES3	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
PTGES3	transfac_pro__M04748	GABPA (directAnnotation).
PTGES3	hdpi__TP73	TP73 (directAnnotation).
PTGES3	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
PTGES3	transfac_pro__M04862	NRF1 (directAnnotation).
PTGES3	metacluster_55.5	ZNF541 (directAnnotation).
PTGES3	metacluster_161.31	PRRX2 (directAnnotation).
PTGES3	metacluster_141.2	E2F2; E2F3 (directAnnotation).
PTGES3	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
PTGES3	transfac_pro__M02089	E2F3 (directAnnotation).
PTGES3	kznf__ZNF90_Imbeault2017_OM_RCADE	ZNF90 (directAnnotation).
PTGES3	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
PTGES3	swissregulon__hs__KLF6	KLF6 (directAnnotation).
PTGES3	transfac_pro__M01303	SP1 (directAnnotation).
PTGES3	jaspar__MA0748.2	YY2 (directAnnotation).
PTGES3	dbtfbs__GMEB2_HepG2_ENCSR745VSQ_merged_N1	GMEB2 (directAnnotation).
PTGES3	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
PTGES3	transfac_pro__M06259	ZNF91 (directAnnotation).
PTGES3	stark__RCGCMATTW	YY1 (inferredBy_Orthology).
PTGES3	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_repr	ZNF385D (directAnnotation).
PTGES3	transfac_pro__M05893	ZNF676 (directAnnotation).
PTGES3	metacluster_198.7	AHR; ZBTB14; ZBTB14; ZBTB14 (directAnnotation).
PTGES3	metacluster_141.9	TAF1; YY1; YY1 (directAnnotation).
PTGES3	taipale_cyt_meth__ZBTB2_NTTTMCGGTWAN_eDBD	ZBTB2 (directAnnotation).
PTGES3	metacluster_144.8	ZNF30; ZNF30 (directAnnotation).
PTGES3	homer__GGCGGGAARN_E2F6	E2F6 (directAnnotation).
PTGES3	kznf__ZNF571_Imbeault2017_OM_RCADE	ZNF571 (directAnnotation).
PTGES3	taipale_cyt_meth__KLF12_NGCCGACGCCCW_FL_meth_repr	KLF12 (directAnnotation).
PTGES3	taipale_tf_pairs__ELK1_EOMES_TNRCACCGGAAGN_CAP	ELK1; EOMES (directAnnotation).
PTGES3	taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP	ELK1; FOXO1 (directAnnotation).
PTGES3	taipale_tf_pairs__ETV2_FOXI1_RNCGGAANNAAACA_CAP_repr	ETV2; FOXI1 (directAnnotation).
PTGES3	taipale_tf_pairs__ERF_TBX21_TMACACCGGAAG_CAP	ERF; TBX21 (directAnnotation).
PTGES3	jaspar__MA1935.1	FOXI1 (directAnnotation).
PTGES3	taipale_tf_pairs__ELK1_TBX21_TNRCACCGGAAGNN_CAP_repr	ELK1; TBX21 (directAnnotation).
PTGES3	metacluster_151.2	ZNF23 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
PTGES3	"Acetaminophen"	DB00316	small molecule
PTGES3	"Copper"	DB09130	small molecule
PTGES3	"Grn163l"	DB05036	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."